Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lumateperone · Caplyta

Small molecule · Antagonist of serotonin 5-HT2A receptor (HTR2A) and dopamine D2 receptor (DRD2) · developed by Intra-Cellular

Approved FDA, Dec 2019

What is Lumateperone?

Lumateperone is an atypical antipsychotic that acts on central serotonin 5-HT2A receptors as an antagonist and on central dopamine D2 receptors as a partial agonist.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Caplyta, lumateparone
Drug type
Small molecule
Targets
serotonin 5-HT2A receptor (HTR2A), dopamine D2 receptor (DRD2)
Mechanism
Antagonist of serotonin 5-HT2A receptor (HTR2A) and dopamine D2 receptor (DRD2)
Therapy area
Psychiatry
Developer
Intra-Cellular
In trials of
JNJ
FDA status
Approved as Caplyta (December 20, 2019), NDA209500 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 20, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Blunted Emotion in Major Depressive Disorder

Other drugs acting on HTR2A / DRD2

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.